Merck's acquisition of Sigma-Aldrich close to completion
Twelve months after pharmaceutical company Merck announced its intention to buy US life science company Sigma-Aldrich, steady progress has been made towards closing the deal.
On 22 September 2014, Merck revealed its agreement with Sigma-Aldrich to purchase the latter for US$17 billion — US$140 cash per share — establishing itself as one of the leading players in the US$130 billion global life science industry. The merged company will be led by Merck Millipore CEO Udit Batra.
On 11 August 2015, Sigma-Aldrich and Merck announced they had obtained all necessary antitrust approvals, with the approval of the European Commission (EC) being conditional upon the sale of parts of Sigma-Aldrich’s solvents and inorganics business in Europe. Negotiations with potential buyers are now in the final stage.
Once a binding agreement has been signed, the EC must approve the buyer before Merck can complete the Sigma-Aldrich acquisition. Completion is expected within the next two months.
CSL fellowships fund immunity research, AI-designed proteins
Australian scientists Dr Carolien van de Sandt and Dr Rhys Grinter have each been awarded CSL...
Leukaemia Foundation funds ongoing blood cancer research at UWA
The $3m in funding is understood to represent the single largest non-government investment in...
Jian Zhou Medal recognises anaesthesia, blood pressure research
The Australian Academy of Health and Medical Sciences has announced Professor Britta Regli-von...
